Journal
STEM CELL RESEARCH & THERAPY
Volume 11, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13287-020-01950-x
Keywords
human embryonic stem cells; stem cell-based tissue model; gene therapy; rAAV; AAV capsids; AAV serotypes; lung organoids; viral infection model; alveolar type II cells
Funding
- Wellcome Trust [110579/Z/15/Z]
- MRC
- MRC [1966167] Funding Source: UKRI
- Wellcome Trust [110579/Z/15/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Gene therapy is being investigated for a range of serious lung diseases, such as cystic fibrosis and emphysema. Recombinant adeno-associated virus (rAAV) is a well-established, safe, viral vector for gene delivery with multiple naturally occurring and artificial serotypes available displaying alternate cell, tissue, and species-specific tropisms. Efficient AAV serotypes for the transduction of the conducting airways have been identified for several species; however, efficient serotypes for human lung parenchyma have not yet been identified. Here, we screened the ability of multiple AAV serotypes to transduce lung bud organoids (LBOs)-a model of human lung parenchyma generated from human embryonic stem cells. Microinjection of LBOs allowed us to model transduction from the luminal surface, similar to dosing via vector inhalation. We identified the naturally occurring rAAV2 and rAAV6 serotypes, along with synthetic rAAV6 variants, as having tropism for the human lung parenchyma. Positive staining of LBOs for surfactant proteins B and C confirmed distal lung identity and suggested the suitability of these vectors for the transduction of alveolar type II cells. Our findings establish LBOs as a new model for pulmonary gene therapy and stress the relevance of LBOs as a viral infection model of the lung parenchyma as relevant in SARS-CoV-2 research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available